CoChat
Sign Up
Cited by 117Lipid metabolism and disordersLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome

Rosenson, Robert S., Wolff, David A., Huskin, Anna L., Helenowski, Irene B., Rademaker, Alfred W.·2007·Diabetes Care
DOI 10.2337/dc07-0015
Open this paper in CoChat — free account

Abstract

OBJECTIVE—The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome. RESEARCH DESIGN AND METHODS—Fifty-nine subjects with fasting hypertriglyceridemia (≥1.7 and <6.9 mmol/l) and two or more of the Adult Treatment Panel III criteria for the metabolic syndrome were randomly assigned to fenofibrate (160 mg/day) or placebo in a double-blind, controlled clinical trial. RESULTS—Fenofibrate treatment lowered fasting triglycerides (−46.1%, P < 0.0001) and postprandial (area under the curve) triglycerides (−45.4%, P < 0.0001) due to significant reductions in postprandial levels of large (−40.8%, P < 0.0001) and medium (−49.5%, P < 0.0001) VLDL particles. The number of fasting total LDL particles was reduced in fenofibrate-treated subjects (−19.0%, P = 0.0033) primarily due to reductions in small LDL particles (−40.3%, P < 0.0001); these treatment differences persisted postprandially. Fasting and postprandial oxidized fatty acids were reduced in fenofibrate-treated subjects compared with placebo-administered subjects (−15.3%, P = 0.0013, and 31.0%, P < 0.0001, respectively), and fenofibrate therapy lowered fasting and postprandial soluble vascular cell adhesion molecule-1 (VCAM-1) (−10.9%, P = 0.0005, and −12.0%, P = 0.0001, respectively) as well as fasting and postprandial soluble intercellular adhesion molecule-1 (ICAM-1) (−14.8%, P < 0.0001, and −15.3%, P < 0.0001, respectively). Reductions in VCAM-1 and ICAM-1 were correlated with reductions in fasting and postprandial large VLDL particles (P < 0.0001) as well as postprandial oxidized fatty acids (P < 0.0005). CONCLUSIONS—Triglyceride-lowering therapy with fenofibrate reduced fasting and postprandial free fatty acid oxidation and inflammatory responses, and these antiatherosclerotic effects were most highly correlated with reductions in large VLDL particles.

Integrity signals

Registry

Crossref · 10.2337/dc07-0015

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rosenson et al. reported that 3 months of fenofibrate therapy (once daily 160 mg) improved lipoproteinemia, oxidative stress, and inflammatory response in subjects with hypertriglyceridemia and metabolic syndrome.

    “Rosenson et al. [73] reported that 3 months of FF therapy (once daily 160mg/dl) improved lipoproteinemia, oxidative stress, and inflammatory response in subjects with hypertriglyceridemia and MetS.”

    From Fenofibrate and metabolic syndrome (2010) · cites this paper as [73]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B., & Rademaker, A. W.
Affiliations
  • University of Michigan (US)
  • Northwestern University (US)
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2007-08-01
Volume
30
Issue
8
Pages
1945-1951
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc07-0015
OpenAlex
W2023823945
Cited by
117
References
48
Citations by year
2025: 5 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 8 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 13
FWCI
11.20
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Abbott Laboratories
  • Northwestern University
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
fenofibrate, hypertriglyceridemia, metabolic syndrome, VLDL particles, small dense LDL, oxidized fatty acids, oxidative stress, VCAM-1, ICAM-1, inflammatory mediators, triglyceride lowering, statin-sparing therapy, fibrate therapy, endothelial inflammation, LDL particle size, lipoprotein oxidation
MeSH terms
Adult, Hypolipidemic Agents, Apolipoproteins B, Blood Glucose, Blood Pressure, Double-Blind Method, Fatty Acids, Nonesterified, Female, Humans, Insulin, Lipids, Lipoproteins, Male, Middle Aged, Placebos, Fenofibrate, Hypertriglyceridemia, Postmenopause, Oxidative Stress, Patient Selection, Intercellular Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review